Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration

While results thus far demonstrate the clinical benefit of trastuzumab, some patients do not respond to this therapy. To identify a molecular predictor of trastuzumab benefit, we conducted whole-transcriptome analysis of primary HER2+ breast carcinomas obtained from patients treated with trastuzumab...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Triulzi, Tiziana, De Cecco, Loris, Sandri, Marco, Prat, Aleix, Giussani, Marta, Paolini, Biagio, Carcangiu, Marialuisa L., Canevari, Silvana, Bottini, Alberto, Balsari, Andrea, Menard, Sylvie, Generali, Daniele, Campiglio, Manuela, Di Cosimo, Serena, Tagliabue, Elda
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2015
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4695052/
https://ncbi.nlm.nih.gov/pubmed/26334217
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky